Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the approval status, mechanism of action, and efficacy of melflufen in multiple myeloma. Melflufen is a peptide-drug conjugate which targets aminopeptidases and releases alkylating agents directly into tumor cells. Dr Richardson discusses the results of the Phase I/IIa ANCHOR trial (NCT03481556) which showed that melflufen and dexamethasone in combination with either bortezomib or daratumumab produced very encouraging response rates. The Phase III LIGHTHOUSE study (NCT03481556), although terminated early, indicated that melflufen combined with daratumumab and dexamethasone provided a therapeutic benefit compared to daratumumab and dexamethasone alone. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK
Research grant: Oncopeptides, Celgene/BMS, Karopharm, Takeda